Aurinia Pharmaceuticals Stock Price, News & Analysis (TSE:AUP)

C$7.09 +0.17 (+2.46 %)
(As of 02/23/2018 04:00 PM ET)
Previous CloseC$6.92
Today's RangeC$6.95 - C$7.16
52-Week RangeC$4.29 - C$14.17
Volume35,454 shs
Average Volume54,506 shs
Market CapitalizationC$585.62 million
P/E Ratio-4.17
Dividend YieldN/A
Beta3.53

About Aurinia Pharmaceuticals (TSE:AUP)

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
SectorTechnology
SymbolTSE:AUP
CUSIPN/A
Phone+1-250-7084272

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-4.16867469879518
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($1.66)
Net IncomeN/A
Net Margins-45,241.38%
Return on Equity-30.41%
Return on Assets-25.82%

Miscellaneous

EmployeesN/A
Outstanding Shares84,052,000

Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

When will Aurinia Pharmaceuticals make its next earnings announcement?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Aurinia Pharmaceuticals.

Who are some of Aurinia Pharmaceuticals' key competitors?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:

  • Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer (Age 57)
  • Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
  • Michael R. Martin, Chief Operating Officer
  • Neil Solomons M.D., Chief Marketing Officer
  • Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
  • Robert B. Huizinga, Vice President - Clinical Affairs
  • Lawrence D. Mandt, Vice President - Regulatory and Quality (Age 57)
  • Joseph P. Hagan, Director (Age 48)
  • George M. Milne Jr., Ph.D., Director (Age 73)
  • Lorin Jeffry Randall, Director (Age 73)

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately C$7.09.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of C$585.62 million.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


MarketBeat Community Rating for Aurinia Pharmaceuticals (AUP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aurinia Pharmaceuticals (TSE:AUP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Aurinia Pharmaceuticals (TSE:AUP) Consensus Price Target History

Price Target History for Aurinia Pharmaceuticals (TSE:AUP)

Aurinia Pharmaceuticals (TSE:AUP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/6/2017Seaport Global SecuritiesReiterated RatingBuyView Rating Details
5/15/2017Leerink SwannReiterated RatingOutperformView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyView Rating Details
11/1/2016MackieReiterated RatingSpeculative BuyView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Aurinia Pharmaceuticals (TSE:AUP) Earnings History and Estimates Chart

Earnings by Quarter for Aurinia Pharmaceuticals (TSE:AUP)

Aurinia Pharmaceuticals (TSE AUP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
11/14/2017Q3 2017C($0.18)C($0.20)C$0.17 millionC$0.04 millionViewN/AView Earnings Details
8/10/2017Q2 2017C($0.17)C($0.04)C$0.08 millionC$0.44 millionViewN/AView Earnings Details
5/15/2017Q1 2017C($0.27)C$0.04 millionViewN/AView Earnings Details
3/9/2017Q4 2016C($0.29)C$0.04 millionViewN/AView Earnings Details
11/4/2016Q3 2016C($0.25)C$0.04 millionViewN/AView Earnings Details
8/5/2016Q2 2016C($0.18)C$0.07 millionViewN/AView Earnings Details
5/11/2016Q1 2016C($0.18)C$0.08 millionViewN/AView Earnings Details
3/18/2016Q4 2015C($0.21)C$0.08 millionViewN/AView Earnings Details
11/13/2015Q3 2015C($0.24)C$0.08 millionViewN/AView Earnings Details
8/11/2015Q2 2015C($0.03)C$0.07 millionViewN/AView Earnings Details
5/15/2015Q1 2015C($0.32)C$0.07 millionViewN/AView Earnings Details
3/30/2015Q4 2014C($0.19)C$0.09 millionViewN/AView Earnings Details
11/12/2014Q3 2014C($0.09)C$0.08 millionViewN/AView Earnings Details
8/14/2014Q2 2014C($0.14)C$0.08 millionViewN/AView Earnings Details
5/15/2014Q1 2014C($0.26)C$0.07 millionViewN/AView Earnings Details
3/31/2014Q4 2013C$0.12C$0.75 millionViewN/AView Earnings Details
11/21/2013Q3 2013C($0.01)C$0.09 millionViewN/AView Earnings Details
8/13/2013Q2 2013C($0.50)C$0.09 millionViewN/AView Earnings Details
4/3/2013Q4 2012C($2.00)ViewN/AView Earnings Details
11/13/2012Q3 2012C($0.50)ViewN/AView Earnings Details
8/14/2012Q2 2012C($0.50)ViewN/AView Earnings Details
5/11/2012Q1 2012C($0.15)ViewN/AView Earnings Details
3/13/2012Q4 2011C($0.60)ViewN/AView Earnings Details
11/10/2011Q3 2011C$0.65ViewN/AView Earnings Details
8/6/2011Q1 2011C($0.65)ViewN/AView Earnings Details
7/29/2011Q2 2011C$0.10ViewN/AView Earnings Details
3/25/2011Q4 2010C($1.00)ViewN/AView Earnings Details
11/9/2010Q3 2010C($0.50)ViewN/AView Earnings Details
8/11/2010Q2 2010C($0.20)ViewN/AView Earnings Details
5/12/2010Q1 2010C($0.60)ViewN/AView Earnings Details
3/24/2010Q4 2009C($0.50)ViewN/AView Earnings Details
11/11/2009Q3 2009C($0.50)ViewN/AView Earnings Details
8/6/2009Q2 2009C($0.90)ViewN/AView Earnings Details
5/14/2009Q1 2009C($1.95)ViewN/AView Earnings Details
3/27/2009Q4 2008C($2.50)ViewN/AView Earnings Details
8/6/2008Q2 2008C($2.50)ViewN/AView Earnings Details
5/6/2008Q1 2008C($2.50)ViewN/AView Earnings Details
3/19/2008Q4 2007C($4.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aurinia Pharmaceuticals (TSE:AUP) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Aurinia Pharmaceuticals (TSE:AUP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aurinia Pharmaceuticals (TSE AUP) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Aurinia Pharmaceuticals (TSE:AUP)

Aurinia Pharmaceuticals (TSE AUP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2017Rashieda GluckInsiderBuy50C$0.10C$5.00
3/23/2016Rashieda GluckInsiderSell1,500C$3.00C$4,500.00
(Data available from 1/1/2013 forward)

Headlines

Aurinia Pharmaceuticals (TSE AUP) News Headlines

Source:
DateHeadline
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of DirectorsAurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
finance.yahoo.com - February 22 at 4:43 PM
Today’s Research Reports on Aurinia Pharmaceuticals, Crescita Therapeutics, CanniMed Therapeutics and Titan MedicalToday’s Research Reports on Aurinia Pharmaceuticals, Crescita Therapeutics, CanniMed Therapeutics and Titan Medical
finance.yahoo.com - February 20 at 9:13 AM
Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness ProgramAurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
finance.yahoo.com - February 14 at 9:03 AM
Aurinia to Present at Leerink Partners 7th Annual Global Healthcare ConferenceAurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 6 at 9:01 AM
Toronto Exchanges Stock Review, Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics InternationalToronto Exchanges Stock Review, Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International
finance.yahoo.com - January 16 at 9:03 AM
Edited Transcript of AUP.TO earnings conference call or presentation 14-Nov-17 9:30pm GMTEdited Transcript of AUP.TO earnings conference call or presentation 14-Nov-17 9:30pm GMT
finance.yahoo.com - January 15 at 5:48 PM
Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf ProspectusAurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
finance.yahoo.com - January 4 at 5:50 PM
Aurinia Pharmaceuticals Inc (AUPH) Shares Dip on New Shelf RegistrationAurinia Pharmaceuticals Inc (AUPH) Shares Dip on New Shelf Registration
finance.yahoo.com - January 4 at 5:50 PM
Is Aurinia Pharmaceuticals a Buy?Is Aurinia Pharmaceuticals a Buy?
finance.yahoo.com - December 19 at 8:57 AM
Canadian Exchanges Stock Scanner Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics InternationalCanadian Exchanges Stock Scanner Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International
finance.yahoo.com - December 14 at 9:01 AM
Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech IndexAurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index
finance.yahoo.com - December 12 at 9:23 AM
Aurinia Pharmaceuticals Added to the NASDAQ Biotech IndexAurinia Pharmaceuticals Added to the NASDAQ Biotech Index
finance.yahoo.com - December 11 at 4:16 PM
Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017
finance.yahoo.com - November 23 at 3:38 PM
FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP)FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP)
www.americanbankingnews.com - November 22 at 5:54 AM
Brokers Issue Forecasts for Aurinia Pharmaceuticals Incs Q4 2017 Earnings (AUP)Brokers Issue Forecasts for Aurinia Pharmaceuticals Inc's Q4 2017 Earnings (AUP)
www.americanbankingnews.com - November 17 at 10:12 PM
FY2017 Earnings Estimate for Aurinia Pharmaceuticals Inc (AUP) Issued By Leerink SwannFY2017 Earnings Estimate for Aurinia Pharmaceuticals Inc (AUP) Issued By Leerink Swann
www.americanbankingnews.com - November 17 at 8:08 PM
14 Stocks Moving In Tuesdays After-Hours Session - Benzinga14 Stocks Moving In Tuesday's After-Hours Session - Benzinga
www.benzinga.com - November 15 at 2:43 AM
Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights - Business Wire (press release)Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights - Business Wire (press release)
www.businesswire.com - November 15 at 2:43 AM
Aurinia Pharmaceuticals Inc (AUP) Set to Announce Quarterly Earnings on TuesdayAurinia Pharmaceuticals Inc (AUP) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 8 at 10:14 AM
Cramers lightning round: Im concerned about GameStop ahead of the holidays - CNBCCramer's lightning round: I'm concerned about GameStop ahead of the holidays - CNBC
www.cnbc.com - November 4 at 5:46 PM
Aurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline DevelopmentAurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline Development
seekingalpha.com - October 31 at 3:12 AM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : October 23, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : October 23, 2017
finance.yahoo.com - October 23 at 3:57 PM
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry ... - Business Wire (press release)Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry ... - Business Wire (press release)
www.businesswire.com - October 21 at 8:58 PM
Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap - Motley FoolWhy High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap - Motley Fool
www.fool.com - October 15 at 2:06 AM
Should You Buy Aurinia Pharmaceuticals Inc (AUPH)?Should You Buy Aurinia Pharmaceuticals Inc (AUPH)?
finance.yahoo.com - October 13 at 9:50 PM
Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt CheapWhy High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
finance.yahoo.com - October 13 at 4:50 PM
Millennial investor mindful of Indigenous rights and climate change - The Globe and MailMillennial investor mindful of Indigenous rights and climate change - The Globe and Mail
www.theglobeandmail.com - October 7 at 4:51 PM
Research Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics InternationalResearch Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International
finance.yahoo.com - October 3 at 3:57 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 29, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 29, 2017
finance.yahoo.com - October 2 at 4:07 PM
Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : October 2, 2017Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : October 2, 2017
finance.yahoo.com - October 2 at 4:07 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 13, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 13, 2017
finance.yahoo.com - September 13 at 5:25 PM
Aurinia Pharmaceuticals stock has tripled so far in 2017. Heres why that could be just the start. - Motley FoolAurinia Pharmaceuticals stock has tripled so far in 2017. Here's why that could be just the start. - Motley Fool
www.fool.com - September 2 at 8:54 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : September 1, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : September 1, 2017
finance.yahoo.com - September 1 at 4:45 PM
Too Many People Own StocksToo Many People Own Stocks
finance.yahoo.com - August 31 at 9:10 PM
Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.27) Per Share (AUP)Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.27) Per Share (AUP)
www.americanbankingnews.com - August 28 at 2:28 AM
3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
finance.yahoo.com - August 25 at 2:20 AM
Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
finance.yahoo.com - August 15 at 5:08 PM
Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 10:36 PM
Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : August 1, 2017Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : August 1, 2017
finance.yahoo.com - August 1 at 11:40 PM
Aurinia Pharmaceuticals Inc (TSE:AUP) Set to Announce Earnings on ThursdayAurinia Pharmaceuticals Inc (TSE:AUP) Set to Announce Earnings on Thursday
www.americanbankingnews.com - July 27 at 7:16 AM
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again - Motley Fool3 Been-There-Done-That Biotech CEOs Who Are Doing it Again - Motley Fool
www.fool.com - July 21 at 10:42 PM
Billionaires Bet Big On Canada’s Cannabis FrenzyBillionaires Bet Big On Canada’s Cannabis Frenzy
www.baystreet.ca - July 21 at 5:42 PM
Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : July 18, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : July 18, 2017
finance.yahoo.com - July 18 at 5:41 PM
Cramer Remix: Why its still worth owning Procter & Gamble - CNBCCramer Remix: Why it's still worth owning Procter & Gamble - CNBC
www.cnbc.com - July 18 at 2:33 AM
Cramer Remix: Why it’s still worth owning Procter & GambleCramer Remix: Why it’s still worth owning Procter & Gamble
finance.yahoo.com - July 17 at 9:31 PM
3 Small Biotech Stocks Being Run by Proven Winners - Motley Fool3 Small Biotech Stocks Being Run by Proven Winners - Motley Fool
www.fool.com - July 17 at 12:31 PM
Is Aurinia Pharmaceuticals' Management Its Best Asset?Is Aurinia Pharmaceuticals' Management Its Best Asset?
finance.yahoo.com - July 14 at 11:04 PM
Aurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition RuleAurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition Rule
finance.yahoo.com - July 12 at 9:44 PM
After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy?After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy?
finance.yahoo.com - July 12 at 9:44 PM
Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood ... - Business Wire (press release)Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood ... - Business Wire (press release)
www.businesswire.com - June 7 at 7:41 AM

SEC Filings

Aurinia Pharmaceuticals (TSE:AUP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Aurinia Pharmaceuticals (TSE AUP) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.